Comparative safety of JAK inhibitors versus TNF or IL-17 inhibitors for cardiovascular disease and cancer in psoriatic arthritis and axial spondyloarthritis
Clin. Ther. 2025;47:293–297 doi: 10.1016/j.clinthera.2025.01.005
Zhao et al. found that among patients with PsA or axSpA, JAKi were not associated with increased risk of CVD or common cancers compared to TNFi or IL-17i.
The study analysed real-world electronic health records from a large North American population, comparing JAKi initiators with matched TNFi and IL-17i groups. The key aim was to evaluate the safety profile of JAKi in terms of cardiovascular and cancer risks, considering regulatory warnings previously issued for these treatments.
Keywords:
